ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval and first use of the FlexAbility™ Ablation Catheter, a novel ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias. Designed with feedback from physician thought-leaders around the world, the FlexAbility catheter combines a unique, irrigated flexible catheter tip with a state-of-the-art handle and catheter design. The next-generation flexible tip technology was designed to reduce complications associated with ablation procedures through its ability to bend and conform to the cardiac anatomy, decreasing the amount of pressure distributed to a patient’s heart wall while simultaneously increasing the stability of therapy delivery.
“The goal of the FlexAbility catheter was to bring the most advanced irrigated ablation solution to the electrophysiology market,” said Eric S. Fain, M.D., group president at St. Jude Medical. “Because we worked with industry thought leaders throughout the development of this technology, we are confident that its completely redesigned handle and shaft, along with its unique flexible tip, will become a leading ablation technology that addresses the broad needs of electrophysiologists across the wide spectrum of patient anatomies.”
Ablation catheters, such as the FlexAbility irrigated ablation catheter, are thin, flexible wires used to help treat irregular heartbeats that impair the heart's ability to effectively pump blood throughout the body. Worldwide, an estimated 34 million individuals have atrial fibrillation (AF), the most common type of arrhythmia. The FlexAbility catheter features an innovative handle and shaft that allows for improved maneuverability, enabling electrophysiologists to reach challenging anatomic locations within their patients. The technology was designed to provide optimal irrigation flow over the entire tip for improved cooling, reducing risk factors associated with the delivery of therapy. The first cases that used the FlexAbility catheter post-approval took place at IdealMed Unidade Hospitalar de Coimbra in Coimbra, Portugal by Dr. Andrea Natale and at the Hôpital Haut-Lévèque in Bordeaux, France by Dr. Nicolas Derval.
“The FlexAbility catheter brings technical and functional advancements to the electrophysiology lab through its unique catheter tip and excellent handling capabilities,” said Dr. Natale. “The catheter tip allows for effective lesion formation with potentially fewer risks, representing an important option for electrophysiologists that are looking to broaden their ability to treat arrhythmias with increased confidence.”
Data that are produced by the FlexAbility ablation catheter are displayed on the EnSite™ Velocity™ System, a cardiac mapping and navigation system. Once FlexAbility catheters are inserted in the cardiac chamber the EnSite system records electrical information from the heart and displays it in a three-dimensional anatomical model. The highly detailed anatomical models, or maps, enable physicians to diagnose and guide treatment for abnormal heart rhythms.
The approval of the FlexAbility catheter further strengthens St. Jude Medical’s fast-growing ablation technology portfolio, which also includes the TactiCath™ contact-force sensing irrigated ablation catheter. Approved and commercially available in Europe since 2012, the TactiCath catheter is designed to give physicians a real-time, objective measure of the force applied to the heart wall during a cardiac ablation procedure. The TactiCath and FlexAbility ablation catheters are investigational devices in the United States.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2013 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 29, 2014. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.